MedPath

Zumutor Biologics, Inc.

Zumutor Biologics, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2015-01-01
Employees
11
Market Cap
-
Website
http://www.zumutor.com

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Non Small Cell Lung Cancer
Esophageal Cancer
Prostate Cancer
Urothelial Carcinoma
Triple Negative Breast Cancer
Pancreas Adenocarcinoma
Biliary Tract Cancer
High Grade Ovarian Serous Adenocarcinoma
Diffuse Large B Cell Lymphoma
Head and Neck Squamous Cell Carcinoma
Interventions
First Posted Date
2024-06-11
Last Posted Date
2024-12-04
Lead Sponsor
Zumutor Biologics Inc.
Target Recruit Count
33
Registration Number
NCT06451497
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

NEXT Oncology, San Antonio, Texas, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.